J. Goldman & Co’s Ionis Pharmaceuticals IONS Stock Holding History

J. Goldman & Co’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.2M	Sell	40,366 -194,894	-83%	-$14.7M	0.08%	273
2026 Q1	$17.7M	Buy	235,260 +167,621	+248%	+$13.2M	0.51%	47
2025 Q4	$5.35M	Sell	67,639 -28,559	-30%	-$2.15M	0.14%	183
2025 Q3	$6.29M	Sell	96,198 -51,484	-35%	-$2.51M	0.16%	175
2025 Q2	$5.83M	Sell	147,682 -160,088	-52%	-$5.24M	0.14%	186
2025 Q1	$9.29M	Sell	307,770 -299,729	-49%	-$9.82M	0.23%	134
2024 Q4	$21.2M	Sell	607,499 -1,917	-0.3%	-$71.7K	0.55%	45
2024 Q3	$24.4M	Buy	609,416 +591,914	+3,382%	+$27.5M	0.68%	37
2024 Q2	$834K	Sell	17,502 -213,922	-92%	-$8.77M	0.02%	319
2024 Q1	$10M	Buy	+231,424	New	+$11M	0.32%	101

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

J. Goldman & Co's IONS Position: Q2 2026 in Review

J. Goldman & Co reduced its Ionis Pharmaceuticals (IONS) stake by 83% in Q2 2026, selling an estimated $14.7M and leaving 40,366 shares worth $3.2M. The position accounts for 0.08% of the portfolio, ranked #273.

J. Goldman & Co first reported a position in IONS in Q1 2024 and has held it in 10 quarters since. The position peaked at $24.4M in Q3 2024. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

J. Goldman & Co held 40,366 shares of Ionis Pharmaceuticals worth $3.2M as of Q2 2026.
J. Goldman & Co sold 194,894 Ionis Pharmaceuticals shares in Q2 2026, an estimated $14.7M.
Ionis Pharmaceuticals made up 0.08% of J. Goldman & Co's portfolio in Q2 2026, its #273 holding.
J. Goldman & Co first reported a position in Ionis Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
J. Goldman & Co's Ionis Pharmaceuticals position peaked at $24.4M in Q3 2024.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.